Figure 7: Efficacy of ranibizumab and LAVA2 in the rabbit retinal vascular leakage model.
From: Long-acting protein drugs for the treatment of ocular diseases
LAVA2 at a dose of 210 pmol demonstrated similar efficacy to ranibizumab doses of 6,300 or 10,500 pmol when administered intravitreally 30 days before fluorescein angiography. The terminal vitreal levels (values in brackets above the datapoints) of LAVA2 (8.9 pmol) are higher than the terminal vitreal levels of ranibizumab at all doses (2.4 to 6.2 pmol) even though ranibizumab doses were 22.5- to 50-fold higher than LAVA2 doses. Terminal vitreal levels measured in ng ml−1 were converted to pmoles per eye using a molecular weight of 49 kDa for ranibizumab and 59 kDa for LAVA2. Vitreal volume in rabbit was assumed to be 1.25 ml.
